LEX Diagnostics

LEX Diagnostics is a molecular diagnostics company founded in 2020 and based in Melbourn Science Park, Cambridge, UK. The company focuses on developing ultra-fast PCR-based diagnostic systems for point-of-care settings, including urgent care centers, physician office labs, pharmacies, and hospitals. Their flagship product, the LEX system, provides rapid results for multiplex tests detecting Influenza A, Influenza B, and COVID-19 in approximately 6 minutes, with negative results in under 10 minutes. The LEX system features a fully automated swab-to-result workflow that enhances infection control and reduces hands-on time for healthcare providers. Its compact design and ease of use make it suitable for CLIA-waived settings, promoting accessibility and cost-effectiveness in decentralized testing environments. LEX Diagnostics is expanding its respiratory test portfolio and has plans to include additional tests for various infections. The company is committed to regulatory compliance, having submitted applications for FDA clearance and achieved ISO 13485:2016 certification. Recently, LEX was acquired by QuidelOrtho, aiming to strengthen its position in the point-of-care molecular diagnostics market.

• Employees 44
• Founded 2020